Avillion Announces Royalty Pharma Investment

London (UK) and New York, NY (US) – May 6, 2014 – Avillion LLP, a company focused on co-development and financing of late-stage pharmaceutical candidates from Phase 3 clinical development through marketing approval, announced that Royalty Pharma has become an investor, joining Abingworth LLP and Clarus Ventures.

Source: Original Article